Mankind Pharma Ltd (MANKIND) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Mankind Pharma celebrated 30 years of operation, achieving recognition as the fourth largest pharmaceutical company in India by value and second largest by volume.
- Q4 FY25 revenue reached INR 3,079 crores, a 27% YoY growth, with a 23.1% adjusted EBITDA margin.
- FY25 revenue grew by 19% YoY, with a 26% adjusted EBITDA margin.
- Domestic business revenue in Q4 FY25 grew by 18% YoY, driven by chronic therapy outperformance and the BSV acquisition.
- Consumer healthcare revenue in Q4 FY25 stood at INR 178 crores, a 14% YoY growth, reaching INR 809 crores for FY25 (15% YoY growth).
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.